2021
Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19
Bikdeli B, Chatterjee S, Arora S, Monreal M, Jimenez D, Krumholz HM, Goldhaber SZ, Elkind MSV, Piazza G. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal Of The American College Of Cardiology 2021, 78: 408-411. PMID: 34116145, PMCID: PMC8186447, DOI: 10.1016/j.jacc.2021.06.001.Peer-Reviewed Original ResearchRecent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 JACC State-of-the-Art Review
Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, Gheymati A, Ariannejad H, Hosseini SH, Jamalkhani S, Sholzberg M, Monreal M, Jimenez D, Piazza G, Parikh SA, Kirtane AJ, Eikelboom JW, Connors JM, Hunt BJ, Konstantinides SV, Cushman M, Weitz JI, Stone GW, Krumholz HM, Lip GYH, Goldhaber SZ, Bikdeli B. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2021, 77: 1903-1921. PMID: 33741176, PMCID: PMC7963001, DOI: 10.1016/j.jacc.2021.02.035.Peer-Reviewed Original ResearchConceptsCOVID-19Recent randomized trialsCommon pathophysiological featuresDuration of therapyClinical trial enterpriseMacrovascular thrombosisThromboprophylactic regimensAntithrombotic therapyAntithrombotic strategiesEndothelial injuryFuture RCTsMedical wardsIllness severityRandomized trialsPathophysiological featuresJACC StateAntithrombotic agentsCoronavirus diseasePatientsRCTsTherapyTrialsRegimensThrombosisOutpatients
2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunction
2018
National and Regional Trends in Deep Vein Thrombosis Hospitalization Rates, Discharge Disposition, and Outcomes for Medicare Beneficiaries
Minges KE, Bikdeli B, Wang Y, Attaran RR, Krumholz HM. National and Regional Trends in Deep Vein Thrombosis Hospitalization Rates, Discharge Disposition, and Outcomes for Medicare Beneficiaries. The American Journal Of Medicine 2018, 131: 1200-1208. PMID: 29753792, PMCID: PMC7040884, DOI: 10.1016/j.amjmed.2018.04.033.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisHospitalization ratesVein thrombosisBlack patientsMedicare Standard Analytic FilesProportion of patientsPrincipal discharge diagnosisStandard Analytic FilesSecondary prevention effortsDischarge dispositionHospital lengthInpatient managementReadmission ratesDischarge diagnosisService patientsAdjusted outcomesOutpatient careAnalytic FilesMedicare feeMedicare beneficiariesMortality rateClinical practiceHospitalizationPatientsThrombosis